Kyntra Bio (KYNB) Research & Development (2014 - 2026)
Kyntra Bio (KYNB) posted Research & Development of $7.6 million for Q1 2026, up 4.1% sequentially from $7.3 million in Q4 2025, and down 17.54% YoY from $9.2 million in Q1 2025.
Kyntra Bio (KYNB) Research & Development (2014 - 2026) Analysis & Trends
Kyntra Bio has reported Research & Development for 13 years, with the latest figure at $7.6 million in Q1 2026.
- Quarterly Research & Development fell 17.54% year-over-year to $7.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.9 million (down 67.96% YoY) and the FY2025 annual result came in at $23.5 million, down 75.42% from the prior year.
- Research & Development rose to $7.6 million in Q1 2026 per KYNB's latest filing, from $7.3 million in the prior quarter.
- Over five years, Research & Development peaked at $95.5 million in Q2 2023 and troughed at $1.2 million in Q3 2025.
- A 5-year average of $40.6 million and a median of $35.3 million in 2023 frame the typical range for Research & Development.
- The sharpest annual moves came in 2023 and 2025: Research & Development jumped 34.55% in 2023, then plunged 93.95% in 2025.
- Over 5 years, Research & Development stood at $61.6 million in 2022, then slumped by 42.7% to $35.3 million in 2023, then plunged by 80.55% to $6.9 million in 2024, then climbed by 5.82% to $7.3 million in 2025, then grew by 4.1% to $7.6 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $7.6 million, $7.3 million, and $1.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Kyntra Bio | 29.83 Mn | 29.83 Mn | 1.47 Mn | 6.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.82 Mn |
| Mar 31, 2026 | 7.57 Mn |
| Dec 31, 2025 | 7.27 Mn |
| Sep 30, 2025 | 1.21 Mn |
| Jun 30, 2025 | 5.87 Mn |
| Mar 31, 2025 | 9.18 Mn |
| Dec 31, 2024 | 6.87 Mn |
| Sep 30, 2024 | 19.97 Mn |
| Jun 30, 2024 | 32.36 Mn |
| Mar 31, 2024 | 36.49 Mn |
| Dec 31, 2023 | 35.32 Mn |
| Sep 30, 2023 | 61.19 Mn |
| Jun 30, 2023 | 95.48 Mn |
| Mar 31, 2023 | 74.49 Mn |
| Dec 31, 2022 | 61.63 Mn |
| Sep 30, 2022 | 75.18 Mn |
| Jun 30, 2022 | 70.96 Mn |
| Mar 31, 2022 | 89.02 Mn |
| Dec 31, 2021 | 113.92 Mn |
| Sep 30, 2021 | 75.88 Mn |